Anscher, M. S., Chang, E., Gao, X., Gong, Y., Weinstock, C., Bloomquist, E., . . . Beaver, J. A. (2020). FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer. Oncologist.
Style de citation ChicagoAnscher, Mitchell S., et al. "FDA Approval Summary: Rucaparib for the Treatment of Patients With Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer." Oncologist 2020.
Style de citation MLAAnscher, Mitchell S., et al. "FDA Approval Summary: Rucaparib for the Treatment of Patients With Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer." Oncologist 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.